ARADIGM CORP
Healthcare · Electromedical & Electrotherapeutic Apparatus · CA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7M | $6,000 | $8.8M | $6.6M | $279,000 | $282,000 |
| Operating income | −$2.8M | −$8.1M | −$1.1M | −$822,000 | −$2.9M | −$1.6M |
| Net income | −$10.7M | −$32.9M | −$17.2M | $4.7M | −$21.6M | −$2.0M |
| Total assets | $8.1M | $25.1M | $35.6M | $54.0M | $50.4M | $9.0M |
| Total liabilities | $20.6M | $24.1M | $12.5M | $14.8M | $16.7M | $10.4M |
| Equity | −$12.5M | $987,000 | $23.1M | $39.1M | $33.7M | −$1.4M |
| EPS (diluted) | $14800.00 | — | $-1.17 | $0.53 | $-2.36 | — |
| Shares out. | 15.0M | 14.8M | 14.7M | 587.3M | 251.3M | 198.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −163.0%
- Net margin
- −632.3%
- Return on equity
- 85.4%
- Return on assets
- −132.7%
- Return on capital (ROCE)
- −106.2%
- Liabilities / assets
- 255.4%
- Debt / equity
- —
- Book value / share
- $-0.84
- Revenue growth (YoY)
- 28116.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -185.12distress
- Accruals / assets
- 71.8%high accruals
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Other material eventJun 15, 2020
- Other material eventJun 4, 2020
- Other material eventApr 30, 2020
- Other material eventApr 13, 2020
- Other material eventApr 3, 2020
- Entered a material agreement · Other material eventMar 9, 2020
- Entered a material agreementFeb 21, 2020
- Other material eventOct 31, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.